Breaking News
1 hour ago
Pharma Now Editorial Team

Pharma Now Editorial Team
Pharma Now Editorial Team
Pharma Now Editorial Team
Pharma Now Editorial Team
Ipsen withdraws Tazverik on safety signals while rare disease sales surge 125% CER and three Phase III readouts loom in H2 2026.
Pharma Now Editorial Team

Roche Q1 2026 pipeline advances in MS and obesity signal near-term CMO scale-up demands as Phase III data matures.
Pharma Now Editorial Team

Sanofi posts five Q1 immunology approvals and 13.6% CER sales growth, raising near-term GMP capacity and compliance demands.
Pharma Now Editorial Team

Orion Pharma launches TEADCO basket trial testing ODM-212 across mesothelioma, NSCLC, and pancreatic cancer combination regimens.
Pharma Now Editorial Team
